AptarGroup (ATR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
6 May, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who announced his retirement after nearly 10 years and introduced his successor, who will assume the role in September 2026 and join the board at year-end.
The meeting was held virtually to increase accessibility, with the agenda and rules available online.
Board members, executive officers, and independent accountants were introduced.
Board and executive committee updates
The CEO will remain in his role until September 2026 and then serve as an advisor through year-end to ensure a smooth leadership transition.
The incoming CEO expressed enthusiasm for the new role and appreciation for the outgoing CEO's leadership.
Overview of voting outcomes
A quorum was confirmed, and polls were open for voting on all agenda items.
Four directors were elected to serve until the 2029 annual meeting.
Executive compensation was approved on an advisory basis.
The appointment of the independent registered public accounting firm for 2026 was ratified.
Latest events from AptarGroup
- Sales up 11% but margin pressure and pharma destocking weighed on profit; Q2 growth expected.ATR
Q1 20265 May 2026 - Q4 2025 sales up 14% but net income down 26%; $600M share buyback authorized.ATR
Q4 202517 Apr 2026 - Pharma innovation, digital health, and sustainability drive robust growth and future outlook.ATR
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Proxy covers director elections, pay, auditor ratification, and strong ESG and governance focus.ATR
Proxy filing27 Mar 2026 - Annual meeting covers director elections, say-on-pay, and auditor ratification.ATR
Proxy filing27 Mar 2026 - Pharma-led innovation, sustainability, and disciplined capital drive robust 2025 results and outlook.ATR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - 2025 growth led by pharma and innovation, with margin expansion and global operational strength.ATR
Bank of America 2026 Global Agriculture and Materials Conference2 Mar 2026 - Profitable growth driven by innovation, efficiency, and strong shareholder returns.ATR
Investor Day 20253 Feb 2026 - Q2 adjusted EPS up 12% to $1.37, driven by Pharma growth and margin gains.ATR
Q2 20242 Feb 2026